Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $53 Price Target
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $53 price target.
Stocks · News reference
Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Apple To $370? Here Are 10 Top Analyst Forecasts For Thursday
Analysts cut targets for AAPL, CHWY, COO, TYRA and CNM; raised DLR, DPZ, SIG, while ratings stayed unchanged.
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $45 to $30.
Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.